First Eagle Investment Management LLC Holds Position in Vascular Biogenics Ltd. (VBLT)
First Eagle Investment Management LLC maintained its stake in Vascular Biogenics Ltd. (NASDAQ:VBLT) during the third quarter, according to its most recent disclosure with the SEC. The fund owned 923,239 shares of the biopharmaceutical company’s stock at the end of the third quarter. First Eagle Investment Management LLC owned about 3.91% of Vascular Biogenics worth $4,819,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Menta Capital LLC boosted its stake in Vascular Biogenics by 4.1% in the second quarter. Menta Capital LLC now owns 33,200 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 1,300 shares during the last quarter. Turner Investments L.P. purchased a new stake in Vascular Biogenics during the second quarter worth approximately $1,007,000. Macquarie Group Ltd. purchased a new stake in Vascular Biogenics during the second quarter worth approximately $1,521,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Vascular Biogenics during the second quarter worth approximately $1,844,000. Finally, Franklin Resources Inc. purchased a new stake in Vascular Biogenics during the second quarter worth approximately $4,191,000. Hedge funds and other institutional investors own 14.93% of the company’s stock.
Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) traded down 5.31% on Wednesday, hitting $5.35. 282,201 shares of the stock traded hands. The stock has a 50 day moving average of $4.99 and a 200 day moving average of $4.44. The company’s market cap is $143.78 million. Vascular Biogenics Ltd. has a one year low of $2.76 and a one year high of $7.58.
Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings results on Thursday, November 10th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. Equities analysts anticipate that Vascular Biogenics Ltd. will post ($0.60) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “First Eagle Investment Management LLC Holds Position in Vascular Biogenics Ltd. (VBLT)” was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally copied and republished in violation of United States & international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2016/11/30/first-eagle-investment-management-llc-holds-position-in-vascular-biogenics-ltd-vblt.html.
VBLT has been the topic of a number of recent analyst reports. Chardan Capital set a $20.00 price target on shares of Vascular Biogenics and gave the company a “buy” rating in a report on Tuesday. Zacks Investment Research upgraded shares of Vascular Biogenics from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a report on Tuesday, November 15th. HC Wainwright restated a “buy” rating on shares of Vascular Biogenics in a report on Monday, November 14th. Finally, Roth Capital restated a “buy” rating and issued a $17.00 target price on shares of Vascular Biogenics in a report on Tuesday, August 16th. Six analysts have rated the stock with a buy rating, Vascular Biogenics presently has a consensus rating of “Buy” and an average target price of $12.58.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.